Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age M Corral-Debrinski, T Horton, MT Lott, JM Shoffner, M Flint Beal, ... Nature genetics 2 (4), 324-329, 1992 | 1089 | 1992 |
Marked changes in mitochondrial DNA deletion levels in Alzheimer brains M Corral-Debrinski, T Horton, MT Lott, JM Shoffner, AC McKee, MF Beal, ... Genomics 23 (2), 471-476, 1994 | 358 | 1994 |
Mitochondrial DNA mutations in human degenerative diseases and aging DC Wallace, JM Shoffner, I Trounce, MD Brown, SW Ballinger, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1271 (1), 141-151, 1995 | 301 | 1995 |
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia KL Bride, TL Vincent, SY Im, R Aplenc, DM Barrett, WL Carroll, R Carson, ... Blood, The Journal of the American Society of Hematology 131 (9), 995-999, 2018 | 202 | 2018 |
Novel mitochondrial DNA deletion found in a renal cell carcinoma TM Horton, JA Petros, A Heddi, J Shoffner, AE Kaufman, SD Graham Jr, ... Genes, Chromosomes and Cancer 15 (2), 95-101, 1996 | 201 | 1996 |
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro TM Horton, A Gannavarapu, SM Blaney, DZ D’Argenio, SE Plon, SL Berg Cancer chemotherapy and pharmacology 58, 13-23, 2006 | 195 | 2006 |
The 10,400-and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor LR Gooding, TS Ranheim, AE Tollefson, L Aquino, P Duerksen-Hughes, ... Journal of virology 65 (8), 4114-4123, 1991 | 192 | 1991 |
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study TM Horton, D Pati, SE Plon, PA Thompson, LR Bomgaars, PC Adamson, ... Clinical cancer research 13 (5), 1516-1522, 2007 | 174 | 2007 |
The E1B 19,000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytolysis of human cells but not of mouse cells LR Gooding, L Aquino, PJ Duerksen-Hughes, D Day, TM Horton, SP Yei, ... Journal of virology 65 (6), 3083-3094, 1991 | 162 | 1991 |
JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias C Delgado-Martin, LK Meyer, BJ Huang, KA Shimano, MS Zinter, ... Leukemia 31 (12), 2568-2576, 2017 | 140 | 2017 |
Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients TM Horton, BH Graham, M Corral-Debrinski, JM Shoffner, AE Kaufman, ... Neurology 45 (10), 1879-1883, 1995 | 139 | 1995 |
Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015) SM Blaney, M Bernstein, K Neville, J Ginsberg, B Kitchen, T Horton, ... Journal of clinical oncology 22 (23), 4804-4809, 2004 | 129 | 2004 |
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group R Aplenc, S Meshinchi, L Sung, T Alonzo, J Choi, B Fisher, R Gerbing, ... Haematologica 105 (7), 1879, 2020 | 125 | 2020 |
Adenovirus E3 14.7 K protein functions in the absence of other adenovirus proteins to protect transfected cells from tumor necrosis factor cytolysis TM Horton, TS Ranheim, L Aquino, DI Kusher, SK Saha, CF Ware, ... Journal of virology 65 (5), 2629-2639, 1991 | 106 | 1991 |
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4 CR Cruz, U Gerdemann, AM Leen, JA Shafer, S Ku, B Tzou, TM Horton, ... Clinical Cancer Research 17 (22), 7058-7066, 2011 | 105 | 2011 |
Poly (ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O 6-methylguanine … TM Horton, G Jenkins, D Pati, L Zhang, ME Dolan, A Ribes-Zamora, ... Molecular cancer therapeutics 8 (8), 2232-2242, 2009 | 104 | 2009 |
Bortezomib reinduction chemotherapy in high‐risk ALL in first relapse: a report from the Children's Oncology Group TM Horton, JA Whitlock, X Lu, MM O'Brien, MJ Borowitz, M Devidas, ... British journal of haematology 186 (2), 274-285, 2019 | 97 | 2019 |
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre … PD Cole, KM McCarten, Q Pei, M Spira, ML Metzger, RA Drachtman, ... The Lancet Oncology 19 (9), 1229-1238, 2018 | 91 | 2018 |
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916) JA Muscal, PA Thompson, TM Horton, AM Ingle, CH Ahern, RM McGovern, ... Pediatric blood & cancer 60 (3), 390-395, 2013 | 86 | 2013 |
Children's Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma DT Teachey, M Devidas, BL Wood, Z Chen, RJ Hayashi, ML Hermiston, ... Journal of Clinical Oncology 40 (19), 2106-2118, 2022 | 80 | 2022 |